Menu
Back to Journals » Research and Reports in Urology » Volume 5
Sensorimotor polyneuropathy and foot-drop as result of a prostate cancer paraneoplastic syndrome
Authors Bodkin J, Duff M, Seereiter P, Chevli K
Received 9 August 2013
Accepted for publication 7 October 2013
Published 6 December 2013 Volume 2013:5 Pages 159—162
DOI https://doi.org/10.2147/RRU.S52712
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
John J Bodkin,1 Michael Duff,1,2 Phillip J Seereiter Jr,3 K Kent Chevli1,3
1State University of New York School of Medicine and Biomedical Sciences Department of Urology, Buffalo; 2Cancer Care of Western New York, Cheektowaga; 3Western New York Urology Associates, Cheektowaga, NY, USA
Abstract: Paraneoplastic syndromes (PNS) vary in incidence and manifestation based on tumor histology. PNS secondary to urologic malignancies have an extremely low incidence. Most reported cases of PNS from urologic malignancies are associated with adenocarcinoma. Peripheral neuropathy-associated PNS from urologic malignancy are exceedingly rare. An 80-year-old male developed a paraneoplastic sensorimotor polyneuropathy and foot-drop after a diagnosis of clinical stage T2cN0M0, Gleason grade 5+4 prostate cancer. A thorough workup is needed in order to adequately assess and treat PNS. Careful analysis must be used to determine the root cause of a patient's symptoms.
Keywords: prostate cancer, paraneoplastic syndrome, intensity-modulated radiation therapy, peripheral neuropathy
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.